D. Boral Capital Reiterates “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports.

AVXL has been the subject of a number of other reports. Wall Street Zen downgraded shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 23rd. HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, October 7th. Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Wednesday, November 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $44.00.

Anavex Life Sciences Stock Performance

Shares of AVXL stock traded up $0.26 during mid-day trading on Wednesday, hitting $3.72. 2,209,682 shares of the stock traded hands, compared to its average volume of 1,386,933. The firm has a market cap of $319.08 million, a price-to-earnings ratio of -6.52 and a beta of 0.92. The company’s 50-day simple moving average is $7.67 and its 200-day simple moving average is $8.91. Anavex Life Sciences has a twelve month low of $2.86 and a twelve month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same quarter last year, the business posted ($0.14) earnings per share. Analysts forecast that Anavex Life Sciences will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of AVXL. State of Wyoming purchased a new position in Anavex Life Sciences during the second quarter valued at approximately $26,000. AlphaQuest LLC bought a new position in shares of Anavex Life Sciences during the 3rd quarter valued at about $29,000. Quarry LP purchased a new position in shares of Anavex Life Sciences during the 3rd quarter valued at about $36,000. SBI Securities Co. Ltd. boosted its stake in Anavex Life Sciences by 470.0% in the second quarter. SBI Securities Co. Ltd. now owns 4,879 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,023 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Anavex Life Sciences by 11,540.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 6,924 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.